CCL20-CCR6轴、CA125联合预测急性心肌梗死PCI术后疾病转归的临床价值  

Clinical value of CCL20-CCR6 axis combined with CA125 in predicting disease outcome after PCI in acute myocardial infarction

作　　者：黄青[1] 黄广伟 曹光营 詹鹏[1] HUANG Qing;HUANG Guangwei;CAO Guangying;ZHAN Peng(Department of Cardiovascular Medicine,Anshun People′s Hospital,Anshun,Guizhou 561000,China)

机构地区：[1]安顺市人民医院心血管内科,贵州安顺561000

出　　处：《国际检验医学杂志》2024年第20期2471-2475,共5页International Journal of Laboratory Medicine

基　　金：2020年贵州省科教青年英才培训工程项目(黔省专合字[2020]117号)。

摘　　要：目的探讨趋化因子配体20(CCL20)-趋化因子受体6(CCR6)轴、糖类抗原125(CA125)联合预测急性心肌梗死(AMI)疾病转归的临床价值。方法选取2022年1月至2023年1月该院98例AMI患者作为研究组,另选取同期49例体检健康者作为对照组。比较两组血清CCL20、CCR6、CA125水平,并比较研究组不同冠脉病变严重程度患者入院时血清CCL20、CCR6、CA125水平,分析研究组血清CCL20、CCR6、CA125水平与冠脉病变严重程度的相关性。研究组均行经皮冠状动脉介入治疗,根据治疗后6个月内是否发生主要心血管不良事件分为预后良好组、预后不良组,比较两组临床资料、入院时血清CCL20、CCR6、CA125水平,分析预后不良的影响因素,并分析入院时血清CCL20、CCR6、CA125水平预测预后不良的价值。结果研究组血清CCL20、CCR6、CA125水平高于对照组(P<0.05);冠脉病变严重程度重度患者血清CCL20、CCR6、CA125水平高于中度、轻度患者,中度患者高于轻度患者(P<0.05);研究组血清CCL20、CCR6、CA125水平与冠脉病变严重程度呈正相关(P<0.05);预后不良组年龄、冠脉病变严重程度、既往心肌梗死史及血清CCL20、CCR6、CA125水平高于预后良好组(P<0.05);年龄、既往心肌梗死史、血清CCL20、CCR6、CA125水平均为AMI患者PCI后预后不良的影响因素(P<0.05);入院时血清CCL20、CCR6、CA125单独预测AMI患者PCI后预后不良的曲线下面积(AUC)分别为0.762、0.819、0.778,各指标联合预测的AUC为0.936,大于各指标单独预测的AUC(P<0.05)。结论入院时血清CCL20、CCR6、CA125水平联合在预测AMI患者PCI后预后不良方面具有较高预测效能,可为临床预测患者疾病转归方向提供可靠依据。Objective To investigate the clinical value of chemokine ligand 20(CCL20)-chemokine receptor 6(CCR6)axis combined with carbohydrate antigen 125(CA125)in predicting the outcome of acute myocardial infarction(AMI).Methods A total of 98 patients with AMI from January 2022 to January 2023 were selected as the study group and 49 healthy subjects were selected as the control group.The serum levels of CCL20,CCR6 and CA125 in the two groups were compared,and the serum levels of CCL20,CCR6 and CA125 in patients with different severity of coronary lesions in the study group were compared at admission,and the correlation between the serum levels of CCL20,CCR6 and CA125 in the study group and the severity of coronary lesions was analyzed.All the study groups were treated with percutaneous coronary intervention,and were divided into good prognosis group and poor prognosis group according to whether major cardiovascular adverse events occurred within 6 months after treatment.The clinical data and serum levels of CCL20,CCR6 and CA125 at admission were compared between the two groups,and the influencing factors of poor prognosis were analyzed,and the value of serum levels of CCL20,CCR6 and CA125 at admission in predicting poor prognosis was analyzed.Results The levels of CCL20,CCR6 and CA125 in the study group were higher than those in the control group(P<0.05).The serum levels of CCL20,CCR6 and CA125 in patients with severe coronary lesions were higher than those in moderate and mild patients,and those in moderate patients were higher than those in mild patients(P<0.05).The serum levels of CCL20,CCR6 and CA125 were positively correlated with the severity of coronary lesions(P<0.05).Age,severity of coronary lesions,history of myocardial infarction,serum levels of CCL20,CCR6 and CA125 in the poor prognosis group were higher than those in the good prognosis group(P<0.05).Age,previous history of myocardial infarction,serum levels of CCL20,CCR6 and CA125 were all influential factors for poor prognosis of AMI patients after PCI(P<0.0

关 键 词：急性心肌梗死 趋化因子配体20 趋化因子受体6 糖类抗原125 预后 

分 类 号：R542.2[医药卫生—心血管疾病]